Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open Label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 Dose Levels of Artefenomel (OZ439) Given in Combination With Ferroquine (FQ) and FQ Alone, in African Patients With Uncomplicated Plasmodium Falciparum Malaria

Trial Profile

A Randomized, Open Label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 Dose Levels of Artefenomel (OZ439) Given in Combination With Ferroquine (FQ) and FQ Alone, in African Patients With Uncomplicated Plasmodium Falciparum Malaria

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2018

At a glance

  • Drugs Artefenomel/ferroquine (Primary) ; Ferroquine (Primary)
  • Indications Falciparum malaria
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 24 Oct 2018 Planned End Date changed from 21 Oct 2019 to 1 Oct 2019.
    • 24 Oct 2018 Planned primary completion date changed from 21 Oct 2019 to 1 Oct 2019.
    • 25 Sep 2018 Planned End Date changed from 1 Sep 2019 to 21 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top